Hikma Egypt Factsheet

November 2025

Hikma is a global pharmaceutical company listed on the London Stock Exchange providing customers across North America, MENA and Europe with a broad range of generic, specialty and branded pharmaceutical products. In Egypt, Hikma is a leading provider of high-quality medicines serving healthcare professionals and patients across the country for over 15 years.



Local expertise, global strength



Manufacturing plants



1,000+

Supporting patients on their health journey

We go beyond the production of medicine by developing disease awareness programmes for various therapeutic areas to support patients in managing their health.

Hikma in Egypt is ranked #9 among the pharmaceutical companies based on sales¹

Launching 2-3 new oral oncology products annually

Making healthcare accessible for all

We ensure our world-class medicines are within reach for all, improving access to healthcare in the country

Manufacturing high-quality medicines

Our three strategically located plants produce a variety medicines in key therapeutic areas:

Cephalosporin plant

Delivers high-quality anti-infectives

General formulation plant

Manufactures a wide range of medicines in various dosage forms

Oncology/ Immunosuppressant plant

Dedicated to producing essential cancer treatments with the first immunosuppressant production capabilities in Egypt

A diversified portfolio of medicines

We offer the Egyptian patient over 158 medicines covering 12 therapeutic areas addressing a wide range of healthcare needs:













Oncology

Diabetes

Gastrointestinal

Cardiovascular

Anti-infectives

Hikma's oral oncology plant with a dedicated immunosuppressant production area is the first in **Egypt**

Hikma has a 2.6% market share of the total Egyptian pharmaceutical market¹

Hikma has a 42% market share in the overall Egyptian multiple sclerosis market²

Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA MIDAS® Quarterly value s Market definitions: Includes all therapeutic areas except for those ATC-3 classes that may encompass Nutrients, Infant Formulas TIG; 72X, 73A, V6C, and V6D, in each case reflecting estimates of real-world activity. Copyright ICVIA AII flights reserved. Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: ICVIA MIDAS® Quarterly value as Market deintimac. Oral Multiple Setrosis Medications Market (ATCS M7X) reflecting estimates of real-world activity. Copyright ICVIA all TIG.

Ranked #2 in oral-systemic, oral anti-infectives3

Area - Plot #1